170098-38-1C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1.O.OUSPVLEIQIUNQGE-DBFLIVQGSA-N170098-38-1DTXSID40168794안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 35 reports by companies from 1 notifications to the ECHA C&L Inventory.
개요Alvimopan is a μ-opioid receptor antagonist approved in the U.S. in May 2008 for the treatment of post-operative ileus (POI) – a temporary dysfunction of the gastrointestines. Alvimopan does not penetrate the central nervous system (CNS) and acts as a peripheral antagonist. The molecule inhibits the negative effects of opioids on the gastrointestinal (GI) system without inhibiting the desired analgesic effects of CNS penetrant opioids.
용도Treatment of opioid-induced bowel dysfunction, opioidinduced nausea and vomiting, postoperative ileus, idiopathic constipation, and irritable bowel syndrome (peripherally restricted mu opioid receptor antagonist).
불러오는 중…
불러오는 중…
불러오는 중…